Skip to main content
SpringerLink
Log in
Book cover

Hematopoietic Cell Transplantation in Children with Cancer pp 41–56Cite as

Preparative Regimens

  • Chapter
  • First Online:

  • 937 Accesses

Part of the book series: Pediatric Oncology ((PEDIATRICO))

Abstract

It is important to keep in mind that preparative regimens in hematopoietic cell transplant (HCT) are typically disease specific and have undergone prospective investigation and validation in clinical trials before becoming widely used. Thus, the choice of a specific preparative regimen is usually the result of selecting from a series of regimens that have been shown to be effective for a given disease. Within the group of recommended regimens, consideration should be given to the status of the disease at time of the HCT (more intensive regimens are usually preferred for disease states with high relapse risk) and the patient’s overall health condition (less-intensive regimens are usually preferred for patients with comorbid conditions or to avoid late effects, like infertility). Novel preparative regimens are not recommended outside of a prospective clinical trial. Another important issue in pediatric HCT is that there have been few randomized trials comparing regimens to assess superiority.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  • Altschuler C, Resbeut M, Maraninchi D, Guillet JP, Blaise D, Stoppa AM, Carcassonne Y (1989) Fractionated total body irradiation and allogeneic bone marrow transplantation for standard risk leukemia. Radiother Oncol 16(4):289–295

    PubMed  CAS  Google Scholar 

  • Andersson BS, Madden T, Tran HT, Hu WW, Blume KG, Chow DS, Champlin RE, Vaughan WP (2000) Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study. Biol Blood Marrow Transplant 6(5A):548–554

    PubMed  CAS  Google Scholar 

  • Andolina JR, Neudorf SM, Corey SJ (2012) How I treat childhood CML. Blood 119(8):1821–1830. doi:10.1182/blood-2011-10-380774, blood-2011-10-380774 [pii]

    PubMed  CAS  Google Scholar 

  • Aversa F, Terenzi A, Tabilio A, Falzetti F, Carotti A, Ballanti S, Felicini R, Falcinelli F, Velardi A, Ruggeri L, Aloisi T, Saab JP, Santucci A, Perruccio K, Martelli MP, Mecucci C, Reisner Y, Martelli MF (2005) Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 23(15):3447–3454. doi:10.1200/JCO.2005.09.117, JCO.2005.09.117 [pii]

    PubMed  Google Scholar 

  • Bacigalupo A (2004) Third EBMT/AMGEN workshop on reduced-intensity conditioning allogeneic haemopoietic stem cell transplants (RIC-HSCT), and panel consensus. Bone Marrow Transplant 33(7):691

    PubMed  CAS  Google Scholar 

  • Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, Apperley J, Slavin S, Pasquini M, Sandmaier BM, Barrett J, Blaise D, Lowski R, Horowitz M (2009) Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 15(12):1628–1633. doi:10.1016/j.bbmt.2009.07.004, S1083-8791(09)00323-1 [pii]

    PubMed  Google Scholar 

  • Bartelink I, Bredius R, Ververs T, Raphael M, Vankesteren C, Bierings M, Rademaker C, Denhartigh J, Uiterwaal C, Zwaveling J (2008) Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant 14(1):88–98. doi:10.1016/j.bbmt.2007.09.015

    PubMed  CAS  Google Scholar 

  • Bartelink IH, Bredius RGM, Belitser SV, Suttorp MM, Bierings M, Knibbe CAJ, Egeler M, Lankester AC, Egberts ACG, Zwaveling J (2009) Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematologic stem cell transplantation. Biol Blood Marrow Transplant 15(2):231–241. doi:10.1016/j.bbmt.2008.11.022

    PubMed  CAS  Google Scholar 

  • Beelen DW, Trenschel R, Casper J, Freund M, Hilger RA, Scheulen ME, Basara N, Fauser AA, Hertenstein B, Mylius HA, Baumgart J, Pichlmeier U, Hahn JR, Holler E (2005) Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications. Bone Marrow Transplant 35(3):233–241. doi:10.1038/sj.bmt.1704784

    PubMed  CAS  Google Scholar 

  • Bernardo ME, Zecca M, Piras E, Vacca A, Giorgiani G, Cugno C, Caocci G, Comoli P, Mastronuzzi A, Merli P, La Nasa G, Locatelli F (2008) Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in patients with thalassaemia major. Brit J Haematol 143(4):548–551. doi:10.1111/j.1365-2141.2008.07385.x

    Google Scholar 

  • Blaise D, Maraninchi D, Archimbaud E, Reiffers J, Devergie A, Jouet JP, Milpied N, Attal M, Michallet M, Ifrah N (1992) Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: a randomized trial of a busulfan-Cytoxan versus Cytoxan-total body irradiation as preparative regimen: a report from the Group d’Etudes de la Greffe de Moelle Osseuse [see comments]. Blood 79(10):2578–2582

    PubMed  CAS  Google Scholar 

  • Boelens JJ, Wynn RF, O’Meara A, Veys P, Bertrand Y, Souillet G, Wraith JE, Fischer A, Cavazzana-Calvo M, Sykora KW, Sedlacek P, Rovelli A, Uiterwaal CS, Wulffraat N (2007) Outcomes of hematopoietic stem cell transplantation for Hurler’s syndrome in Europe: a risk factor analysis for graft failure. Bone Marrow Transplant 40(3):225–233. doi:10.1038/sj.bmt.1705718, 1705718 [pii]

    PubMed  CAS  Google Scholar 

  • Boelens JJ, Bartelink I, Lindemans CA, Bierings M (2012) Fludarabine + exposure-targeted busulfan in children with malignant and non-malignant diseases: an effective and low toxic regimen. Biol Blood Marrow Transplant 18(2):S229

    Google Scholar 

  • Bolanos-Meade J, Hartley E, Jones RJ (2006) Long-term follow-up of allogeneic marrow transplantation for acute myelogenous leukemia after treatment with busulfan and cyclophosphamide. Biol Blood Marrow Transplant 12(3):366–367

    PubMed  Google Scholar 

  • Brochstein JA, Kernan NA, Groshen S, Cirrincione C, Shank B, Emanuel D, Laver J, O’Reilly RJ (1987) Allogeneic bone marrow transplantation after hyperfractionated total-body irradiation and cyclophosphamide in children with acute leukemia. N Engl J Med 317(26):1618–1624

    PubMed  CAS  Google Scholar 

  • Bunin N, Aplenc R, Kamani N, Shaw K, Cnaan A, Simms S (2003) Randomized trial of busulfan vs total body irradiation containing conditioning regimens for children with acute lymphoblastic leukemia: a Pediatric Blood and Marrow Transplant Consortium study. Bone Marrow Transplant 32(6):543–548. doi:10.1038/sj.bmt.1704198, 1704198 [pii]

    PubMed  CAS  Google Scholar 

  • Bunin NJ, Davies SM, Aplenc R, Camitta BM, DeSantes KB, Goyal RK, Kapoor N, Kernan NA, Rosenthal J, Smith FO, Eapen M (2008) Unrelated donor bone marrow transplantation for children with acute myeloid leukemia beyond first remission or refractory to chemotherapy. J Clin Oncol 26(26):4326–4332. doi:10.1200/jco.2008.16.4442

    PubMed  Google Scholar 

  • Carpenter PA, Marshall GM, Giri N, Vowels MR, Russell SJ (1996) Allogeneic bone marrow transplantation for children with acute lymphoblastic leukemia conditioned with busulfan, cyclophosphamide and melphalan. Bone Marrow Transplant 18(3):489–494

    PubMed  CAS  Google Scholar 

  • Casper J, Knauf W, Kiefer T, Wolff D, Steiner B, Hammer U, Wegener R, Kleine HD, Wilhelm S, Knopp A, Hartung G, Dolken G, Freund M (2004) Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation. Blood 103(2):725–731. doi:10.1182/blood-2002-11-3615

    PubMed  CAS  Google Scholar 

  • Clift RA, Buckner CD, Thomas ED, Kopecky KJ, Appelbaum FR, Tallman M, Storb R, Sanders J, Sullivan K, Banaji M et al (1987) The treatment of acute non-lymphoblastic leukemia by allogeneic marrow transplantation. Bone Marrow Transplant 2(3):243–258

    PubMed  CAS  Google Scholar 

  • Clift R, Buckner C, Appelbaum F, Bearman S, Petersen F, Fisher L, Anasetti C, Beatty P, Bensinger W, Doney K (1990) Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens [see comments]. Blood 76(9):1867

    PubMed  CAS  Google Scholar 

  • Clift R, Buckner C, Thomas E, Bensinger W, Bowden R, Bryant E, Deeg H, Doney K, Fisher L, Hansen J (1994) Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 84(6):2036–2043

    PubMed  CAS  Google Scholar 

  • Cwynarski K, Roberts IA, Iacobelli S, van Biezen A, Brand R, Devergie A, Vossen JM, Aljurf M, Arcese W, Locatelli F, Dini G, Niethammer D, Niederwieser D, Apperley JF (2003) Stem cell transplantation for chronic myeloid leukemia in children. Blood 102(4):1224–1231. doi:10.1182/blood-2002-12-3637

    PubMed  CAS  Google Scholar 

  • Dalle JH, Wall D, Theoret Y, Duval M, Shaw L, Larocque D, Taylor C, Gardiner J, Vachon MF, Champagne MA (2003) Intravenous busulfan for allogeneic hematopoietic stem cell transplantation in infants: clinical and pharmacokinetic results. Bone Marrow Transplant 32(7):647–651. doi:10.1038/sj.bmt.1704209

    PubMed  CAS  Google Scholar 

  • Danylesko I, Shimoni A, Nagler A (2012) Treosulfan-based conditioning before hematopoietic SCT: more than a BU look-alike. Bone Marrow Transplant 47(1):5–14. doi:10.1038/bmt.2011.88

    PubMed  CAS  Google Scholar 

  • Davies SM, Ramsay NK, Klein JP, Weisdorf DJ, Bolwell B, Cahn JY, Camitta BM, Gale RP, Giralt S, Heilmann C, Henslee-Downey PJ, Herzig RH, Hutchinson R, Keating A, Lazarus HM, Milone GA, Neudorf S, Perez WS, Powles RL, Prentice HG, Schiller G, Socie G, Vowels M, Wiley J, Yeager A, Horowitz MM (2000) Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia. J Clin Oncol 18(2):340–347

    PubMed  CAS  Google Scholar 

  • de Lima M, Couriel D, Thall PF, Wang X, Madden T, Jones R, Shpall EJ, Shahjahan M, Pierre B, Giralt S, Korbling M, Russell JA, Champlin RE, Andersson BS (2004) Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 104(3):857–864. doi:10.1182/blood-2004-02-0414, 2004-02-0414 [pii]

    PubMed  Google Scholar 

  • Devergie A, Blaise D, Attal M, Tigaud J, Jouet J, Vernant J, Bordigoni P, Ifrah N, Dauriac C, Cahn J (1995) Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: a randomized trial of busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: a report from the French Society of Bone Marrow Graft (SFGM). Blood 85(8):2263

    PubMed  CAS  Google Scholar 

  • Dusenbery KE, Daniels KA, McClure JS, McGlaver PB, Ramsay NKC, Blazar BR, Neglia JP, Kersey JH, Woods WG (1995) Randomized comparison of cyclophosphamide-total body irradiation versus busulfan-cyclophosphamide conditioning in autologous bone marrow transplantation for acute myeloid leukemia. Int J Radiat Oncol Biol Phys 31(1):119–128

    PubMed  CAS  Google Scholar 

  • Eapen M, Rubinstein P, Zhang MJ, Camitta BM, Stevens C, Cairo MS, Davies SM, Doyle JJ, Kurtzberg J, Pulsipher MA, Ortega JJ, Scaradavou A, Horowitz MM, Wagner JE (2006) Comparable long-term survival after unrelated and HLA-matched sibling donor hematopoietic stem cell transplantations for acute leukemia in children younger than 18 months. J Clin Oncol 24(1):145–151. doi:10.1200/JCO.2005.02.4612, 24/1/145 [pii]

    PubMed  Google Scholar 

  • Feig SA, Nesbit ME, Buckley J, Lampkin B, Bernstein ID, Kim TH, Piomelli S, Kersey JH, Coccia PF, O’Reilly RJ et al (1987) Bone marrow transplantation for acute non-lymphocytic leukemia: a report from the Children’s Cancer Study Group of sixty-seven children transplanted in first remission. Bone Marrow Transplant 2(4):365–374

    PubMed  CAS  Google Scholar 

  • Flynn JM, Byrd JC (2000) Campath-1H monoclonal antibody therapy. Curr Opin Oncol 12(6):574–581

    PubMed  CAS  Google Scholar 

  • Gassas A, Sung L, Saunders EF, Doyle JJ (2006) Comparative outcome of hematopoietic stem cell transplantation for pediatric acute lymphoblastic leukemia following cyclophosphamide and total body irradiation or VP16 and total body irradiation conditioning regimens. Bone Marrow Transpl 38(11):739–743

    CAS  Google Scholar 

  • Geyer MB, Jacobson JS, Freedman J, George D, Moore V, van de Ven C, Satwani P, Bhatia M, Garvin JH, Bradley MB, Harrison L, Morris E, Della-Latta P, Schwartz J, Baxter-Lowe LA, Cairo MS (2011) A comparison of immune reconstitution and graft-versus-host disease following myeloablative conditioning versus reduced toxicity conditioning and umbilical cord blood transplantation in paediatric recipients. Br J Haematol 155(2):218–234. doi:10.1111/j.1365-2141.2011.08822.x

    PubMed  Google Scholar 

  • Gibson BE, Webb DK, Howman AJ, De Graaf SS, Harrison CJ, Wheatley K, United Kingdom Childhood Leukaemia Working G, The Dutch Childhood Oncology G (2011) Results of a randomized trial in children with Acute Myeloid Leukaemia: medical research council AML12 trial. Br J Haematol 155(3):366–376. doi:10.1111/j.1365-2141.2011.08851.x

    PubMed  CAS  Google Scholar 

  • Giralt S, Estey E, Albitar M, van Besien K, Rondon G, Anderlini P, O’Brien S, Khouri I, Gajewski J, Mehra R, Claxton D, Andersson B, Beran M, Przepiorka D, Koller C, Kornblau S, Korbling M, Keating M, Kantarjian H, Champlin R (1997) Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 89(12):4531–4536

    PubMed  CAS  Google Scholar 

  • Giralt S, Logan B, Rizzo D, Zhang MJ, Ballen K, Emmanouilides C, Nath R, Parker P, Porter D, Sandmaier B, Waller EK, Barker J, Pavletic S, Weisdorf D (2007) Reduced-intensity conditioning for unrelated donor progenitor cell transplantation: long-term follow-up of the first 285 reported to the national marrow donor program. Biol Blood Marrow Transplant 13(7):844–852. doi:10.1016/j.bbmt.2007.03.011, S1083-8791(07)00217-0 [pii]

    PubMed  Google Scholar 

  • Granados E, de La Camara R, Madero L, Diaz MA, Martin-Regueira P, Steegmann JL, Arranz R, Figuera A, Fernandez-Ranada JM (2000) Hematopoietic cell transplantation in acute lymphoblastic leukemia: better long term event-free survival with conditioning regimens containing total body irradiation. Haematologica 85(10):1060–1067

    PubMed  CAS  Google Scholar 

  • Grochow LB (1993) Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens. Semin Oncol 20(4 Suppl 4):18–25; quiz 26

    PubMed  CAS  Google Scholar 

  • Grochow LB, Jones RJ, Brundrett RB, Braine HG, Chen TL, Saral R, Santos GW, Colvin OM (1989) Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol 25(1):55–61

    PubMed  CAS  Google Scholar 

  • Gyurkocza B, Storb R, Storer BE, Chauncey TR, Lange T, Shizuru JA, Langston AA, Pulsipher MA, Bredeson CN, Maziarz RT, Bruno B, Petersen FB, Maris MB, Agura E, Yeager A, Bethge W, Sahebi F, Appelbaum FR, Maloney DG, Sandmaier BM (2010) Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. J Clin Oncol 28(17):2859–2867. doi:10.1200/JCO.2009.27.1460, JCO.2009.27.1460 [pii]

    PubMed  Google Scholar 

  • Hahn T, Wall D, Camitta B, Davies S, Dillon H, Gaynon P, Larson RA, Parsons S, Seidenfeld J, Weisdorf D, McCarthy PL Jr (2005) The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in children: an evidence-based review. Biol Blood Marrow Transplant 11(11):823–861. doi:10.1016/j.bbmt.2005.08.035, S1083-8791(05)00567-7 [pii]

    PubMed  Google Scholar 

  • Hassan M, Nilsson C, Hassan Z, Gungor T, Aschan J, Winiarski J, Hentschke P, Ringden O, Eber S, Seger R, Ljungman P (2002) A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m(2) as a optimal total dose for conditioning. Bone Marrow Transplant 30(12):833–841

    PubMed  CAS  Google Scholar 

  • Horan JT, Alonzo TA, Lyman GH, Gerbing RB, Lange BJ, Ravindranath Y, Becton D, Smith FO, Woods WG (2008) Impact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: the Children’s Oncology Group. J Clin Oncol 26(35):5797–5801. doi:10.1200/jco.2007.13.5244

    PubMed  Google Scholar 

  • Horn B, Baxter-Lowe LA, Englert L, McMillan A, Quinn M, DeSantes K, Cowan M (2005) Reduced intensity conditioning using intravenous busulfan, fludarabine and rabbit ATG for children with nonmalignant disorders and CML. Bone Marrow Transplant 37(3):263–269

    Google Scholar 

  • Horowitz M, Gale R, Sondel P, Goldman J, Kersey J, Kolb H, Rimm A, Ringden O, Rozman C, Speck B (1990) Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75(3):555–562

    PubMed  CAS  Google Scholar 

  • Johnson FL, Sanders JE, Ruggiero M, Chard RL Jr, Thomas ED (1988) Bone marrow transplantation for the treatment of acute nonlymphoblastic leukemia in children aged less than 2 years. Blood 71(5):1277–1280

    PubMed  CAS  Google Scholar 

  • Kamani NR, Walters MC, Carter S, Aquino V, Brochstein JA, Chaudhury S, Eapen M, Freed BM, Grimley M, Levine JE, Logan B, Moore T, Panepinto J, Parikh S, Pulsipher MA, Sande J, Schultz KR, Spellman S, Shenoy S (2012) Unrelated donor cord blood transplantation for children with severe sickle cell disease: results of one cohort from the phase II study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). Biol Blood Marrow Transplant 18(8):1265–1272. doi:10.1016/j.bbmt.2012.01.019, S1083-8791(12)00058-4 [pii]

    PubMed  Google Scholar 

  • Kashyap A, Wingard J, Cagnoni P, Jones R, Tarantolo S, Hu W, Blume K, Niland J, Palmer JM, Vaughan W (2002) Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. Biol Blood Marrow Transplant 8(9):493–500

    PubMed  CAS  Google Scholar 

  • Kebriaei P, Detry MA, Giralt S, Carrasco-Yalan A, Anagnostopoulos A, Couriel D, Khouri IF, Anderlini P, Hosing C, Alousi A, Champlin RE, de Lima M (2007) Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia. Blood 110(9):3456–3462. doi:10.1182/blood-2007-04-085969, blood-2007-04-085969 [pii]

    PubMed  CAS  Google Scholar 

  • Kletzel M, Jacobsohn D, Duerst R (2006) Pharmacokinetics of a test dose of intravenous busulfan guide dose modifications to achieve an optimal area under the curve of a single daily dose of intravenous busulfan in children undergoing a reduced-intensity conditioning regimen with hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 12(4):472–479. doi:10.1016/j.bbmt.2005.12.028

    PubMed  CAS  Google Scholar 

  • Kolb HJ, Schmid C, Barrett AJ, Schendel DJ (2004) Graft-versus-leukemia reactions in allogeneic chimeras. Blood 103(3):767–776

    PubMed  CAS  Google Scholar 

  • Law J, Cowan MJ, Dvorak CC, Musick L, Long-Boyle JR, Baxter-Lowe LA, Horn B (2012) Busulfan, fludarabine, and alemtuzumab as a reduced toxicity regimen for children with malignant and nonmalignant diseases improves engraftment and graft-versus-host disease without delaying immune reconstitution. Biol Blood Marrow Transplant 18(11):1656–1663. doi:10.1016/j.bbmt.2012.05.006, S1083-8791(12)00196-6 [pii]

    PubMed  CAS  Google Scholar 

  • Lee JH, Choi SJ, Kim SE, Park CJ, Chi HS, Lee MS, Lee JS, Kim WK, Lee KH (2005) Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation. Ann Hematol 84(5):321–330

    PubMed  CAS  Google Scholar 

  • Lee JW, Kang HJ, Lee SH, Yu KS, Kim NH, Yuk YJ, Jang MK, Han EJ, Kim H, Song SH, Park KD, Shin HY, Jang IJ, Ahn HS (2011) Highly variable pharmacokinetics of once-daily intravenous busulfan when combined with fludarabine in pediatric patients: phase I clinical study for determination of optimal once-daily busulfan dose using pharmacokinetic modeling. Biol Blood Marrow Transplant. doi:10.1016/j.bbmt.2011.11.025

    Google Scholar 

  • Locatelli F, Nollke P, Zecca M, Korthof E, Lanino E, Peters C, Pession A, Kabisch H, Uderzo C, Bonfim CS, Bader P, Dilloo D, Stary J, Fischer A, Revesz T, Fuhrer M, Hasle H, Trebo M, van den Heuvel-Eibrink MM, Fenu S, Strahm B, Giorgiani G, Bonora MR, Duffner U, Niemeyer CM (2005) Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial. Blood 105(1):410–419

    PubMed  CAS  Google Scholar 

  • Marsh RA, Vaughn G, Kim MO, Li D, Jodele S, Joshi S, Mehta PA, Davies SM, Jordan MB, Bleesing JJ, Filipovich AH (2010) Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation. Blood 116(26):5824–5831. doi:10.1182/blood-2010-04-282392, blood-2010-04-282392 [pii]

    PubMed  CAS  Google Scholar 

  • Martino R, Badell I, Brunet S, Sureda A, Torras A, Cubells J, Domingo-Albos A (1995) High-dose busulfan and melphalan before bone marrow transplantation for acute nonlymphoblastic leukemia. Bone Marrow Transplant 16(2):209–212

    PubMed  CAS  Google Scholar 

  • Matsuyama T, Kojima S, Kato K (1998) Allogeneic bone marrow transplantation for childhood leukemia following a busulfan and melphalan preparative regimen. Bone Marrow Transplant 22(1):21–26. doi:10.1038/sj.bmt.1701276

    PubMed  CAS  Google Scholar 

  • McDonald GB, Slattery JT, Bouvier ME, Ren S, Batchelder AL, Kalhorn TF, Schoch HG, Anasetti C, Gooley T (2003) Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood 101(5):2043–2048

    PubMed  CAS  Google Scholar 

  • Michel G, Gluckman E, Esperou-Bourdeau H, Reiffers J, Pico JL, Bordigoni P, Thuret I, Blaise D, Bernaudin F, Jouet JP et al (1994) Allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: impact of conditioning regimen without total-body irradiation–a report from the Societe Francaise de Greffe de Moelle. J Clin Oncol 12(6):1217–1222

    PubMed  CAS  Google Scholar 

  • Murphy WJ, Kumar V, Bennett M (1987) Acute rejection of murine bone marrow allografts by natural killer cells and T cells. Differences in kinetics and target antigens recognized. J Exp Med 166(5):1499–1509

    PubMed  CAS  Google Scholar 

  • Nakane T, Nakamae H, Koh H, Nakamae M, Hayashi Y, Nishimoto M, Yoshimura T, Inoue E, Inoue A, Aimoto R, Aimoto M, Terada Y, Koh KR, Yamane T, Hino M (2011) Reduced-intensity conditioning by fludarabine/busulfan without additional irradiation or T-cell depletion leads to low non-relapse mortality in unrelated bone marrow transplantation. Int J Hematol 93(4):509–516. doi:10.1007/s12185-011-0805-z

    PubMed  Google Scholar 

  • Nath CE, Shaw PJ (2007) Busulphan in blood and marrow transplantation: dose, route, frequency and role of therapeutic drug monitoring. Curr Clin Pharmacol 2(1):75–91

    PubMed  CAS  Google Scholar 

  • Nemecek ER, Guthrie KA, Sorror ML, Wood BL, Doney KC, Hilger RA, Scott BL, Kovacsovics TJ, Maziarz RT, Woolfrey AE, Bedalov A, Sanders JE, Pagel JM, Sickle EJ, Witherspoon R, Flowers ME, Appelbaum FR, Deeg HJ (2011) Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies. Biol Blood Marrow Transplant 17(3):341–350. doi:10.1016/j.bbmt.2010.05.007

    PubMed  CAS  Google Scholar 

  • Neudorf S, Sanders J, Kobrinsky N, Alonzo TA, Buxton AB, Gold S, Barnard DR, Wallace JD, Kalousek D, Lange BJ, Woods WG (2004) Allogeneic bone marrow transplantation for children with acute myelocytic leukemia in first remission demonstrates a role for graft versus leukemia in the maintenance of disease-free survival. Blood 103(10):3655–3661. doi:10.1182/blood-2003-08-2705, 2003-08-2705 [pii]

    PubMed  CAS  Google Scholar 

  • Olsson R, Remberger M, Schaffer M, Berggren DM, Svahn BM, Mattsson J, Ringden O (2013) Graft failure in the modern era of allogeneic hematopoietic SCT. Bone Marrow Transplant 48(4):537–543. doi:10.1038/bmt.2012.239, bmt2012239 [pii]

    PubMed  CAS  Google Scholar 

  • Or R, Shapira MY, Resnick I, Amar A, Ackerstein A, Samuel S, Aker M, Naparstek E, Nagler A, Slavin S (2003) Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood 101(2):441–445. doi:10.1182/blood-2002-02-0535, 2002-02-0535 [pii]

    PubMed  CAS  Google Scholar 

  • Pagel JM, Gooley TA, Rajendran J, Fisher DR, Wilson WA, Sandmaier BM, Matthews DC, Deeg HJ, Gopal AK, Martin PJ (2009) Allogeneic hematopoietic cell transplantation after conditioning with 131I–anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome. Blood 114(27):5444

    PubMed  CAS  Google Scholar 

  • Petersdorf EW, Hansen JA, Martin PJ, Woolfrey A, Malkki M, Gooley T, Storer B, Mickelson E, Smith A, Anasetti C (2001) Major-histocompatibility-complex class I alleles and antigens in hematopoietic-cell transplantation. N Engl J Med 345(25):1794–1800

    PubMed  CAS  Google Scholar 

  • Pulsipher MA, Boucher KM, Wall D, Frangoul H, Duval M, Goyal RK, Shaw PJ, Haight AE, Grimley M, Grupp SA, Kletzel M, Kadota R (2009) Reduced-intensity allogeneic transplantation in pediatric patients ineligible for myeloablative therapy: results of the Pediatric Blood and Marrow Transplant Consortium Study ONC0313. Blood 114(7):1429–1436. doi:10.1182/blood-2009-01-196303, blood-2009-01-196303 [pii]

    PubMed  CAS  Google Scholar 

  • Qazilbash MH, Giralt SA, Champlin RE (2004) Nonmyeloablative stem cell transplantation for chronic myeloid leukemia. Hematol Oncol Clin North Am 18(3):703–713, xi. doi:10.1016/j.hoc.2004.03.009 S0889858804000140 [pii]

  • Radich JP, Gooley T, Bensinger W, Chauncey T, Clift R, Flowers M, Martin P, Slattery J, Sultan D, Appelbaum FR (2003) HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. Blood 102(1):31–35

    PubMed  CAS  Google Scholar 

  • Remberger M, Mattsson J, Ringden O (2001) Polyclonal anti-T-cell globulin as part of the preparative regimen for pediatric allogeneic stem-cell transplantation. Pediatric Transplant 5(4):285–292. doi:10.1034/j.1399-3046.2001.005004285.x

    CAS  Google Scholar 

  • Ringden O, Ruutu T, Remberger M, Nikoskelainen J, Volin L, Vindelov L, Parkkali T, Lenhoff S, Sallerfors B, Ljungman P et al (1994) A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. Blood 83(9):2723–2730

    PubMed  CAS  Google Scholar 

  • Ruiz-Arguelles GJ, Gomez-Almaguer D, Morales-Toquero A, Gutierrez-Aguirre CH, Vela-Ojeda J, Garcia-Ruiz-Esparza MA, Manzano C, Karduss A, de-Souza C, Miranda E, Giralt S, Latin American Cooperative Oncohematology G (2005) The early referral for reduced-intensity stem cell transplantation in patients with Ph1 (+) chronic myelogenous leukemia in chronic phase in the imatinib era: results of the Latin American Cooperative Oncohematology Group (LACOHG) prospective, multicenter study. Bone Marrow Transplant 36(12):1043–1047. doi:10.1038/sj.bmt.1705190, 1705190 [pii]

    PubMed  CAS  Google Scholar 

  • Sanders JE, Im HJ, Hoffmeister PA, Gooley TA, Woolfrey AE, Carpenter PA, Andrews RG, Bryant EM, Appelbaum FR (2005) Allogeneic hematopoietic cell transplantation for infants with acute lymphoblastic leukemia. Blood 105(9):3749–3756. doi:10.1182/blood-2004-08-3312, 2004-08-3312 [pii]

    PubMed  CAS  Google Scholar 

  • Santos GW, Tutschka PJ, Brookmeyer R, Saral R, Beschorner WE, Bias WB, Braine HG, Burns WH, Elfenbein GJ, Kaizer H et al (1983) Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. New Engl J Med 309(22):1347–1353. doi:10.1056/nejm198312013092202

    PubMed  CAS  Google Scholar 

  • Satwani P, Cooper N, Rao K, Veys P, Amrolia P (2008) Reduced intensity conditioning and allogeneic stem cell transplantation in childhood malignant and nonmalignant diseases. Bone Marrow Transplant 41(2):173–182. doi:10.1038/sj.bmt.1705923, 1705923 [pii]

    PubMed  CAS  Google Scholar 

  • Satwani P, Jin Z, Duffy D, Morris E, Bhatia M, Garvin JH, George D, Bradley MB, Harrison L, Petrillo K, Schwartz J, Foley S, Hawks R, Baxter-Lowe LA, Cairo MS (2013) Transplantation-related mortality, graft failure, and survival after reduced-toxicity conditioning and allogeneic hematopoietic stem cell transplantation in 100 consecutive pediatric recipients. Biol Blood Marrow Transplant 19(4):552–561. doi:10.1016/j.bbmt.2012.12.005, S1083-8791(12)01141-X [pii]

    PubMed  Google Scholar 

  • Schulz AS, Glatting G, Hoenig M, Schuetz C, Gatz SA, Grewendorf S, Sparber-Sauer M, Muche R, Blumstein N, Kropshofer G, Suttorp M, Bunjes D, Debatin KM, Reske SN, Friedrich W (2011) Radioimmunotherapy-based conditioning for hematopoietic cell transplantation in children with malignant and nonmalignant diseases. Blood 117(17):4642–4650. doi:10.1182/blood-2010-06-284349

    PubMed  CAS  Google Scholar 

  • Shaw PJ, Scharping CE, Brian RJ, Earl JW (1994) Busulfan pharmacokinetics using a single daily high-dose regimen in children with acute leukemia. Blood 84:2357–2362

    PubMed  CAS  Google Scholar 

  • Shenoy S, Grossman WJ, DiPersio J, Yu LC, Wilson D, Barnes YJ, Mohanakumar T, Rao A, Hayashi RJ (2005) A novel reduced-intensity stem cell transplant regimen for nonmalignant disorders. Bone Marrow Transplant 35(4):345–352. doi:10.1038/sj.bmt.1704795, 1704795 [pii]

    PubMed  CAS  Google Scholar 

  • Shimoni A (2003) Intravenous busulfan-based conditioning prior to allogeneic hematopoietic stem cell transplantation: myeloablation with reduced toxicity. Exp Hematol 31(5):428–434. doi:10.1016/s0301-472x(03)00047-x

    PubMed  CAS  Google Scholar 

  • Slattery JT, Clift RA, Buckner CD, Radich J, Storer B, Bensinger WI, Soll E, Anasetti C, Bowden R, Bryant E, Chauncey T, Deeg HJ, Doney KC, Flowers M, Gooley T, Hansen JA, Martin PJ, McDonald GB, Nash R, Petersdorf EW, Sanders JE, Schoch G, Stewart P, Storb R, Appelbaum FR (1997) Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood 89(8):3055–3060

    PubMed  CAS  Google Scholar 

  • Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, Varadi G, Kirschbaum M, Ackerstein A, Samuel S, Amar A, Brautbar C, Ben-Tal O, Eldor A, Or R (1998) Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91(3):756–763

    PubMed  CAS  Google Scholar 

  • Smith FO, King R, Nelson G, Wagner JE, Robertson KA, Sanders JE, Bunin N, Emaunel PD, Davies SM (2002) Unrelated donor bone marrow transplantation for children with juvenile myelomonocytic leukaemia. Br J Haematol 116(3):716–724

    PubMed  Google Scholar 

  • Smith AR, Majhail NS, MacMillan ML, DeFor TE, Jodele S, Lehmann LE, Krance R, Davies SM (2011) Hematopoietic cell transplantation comorbidity index predicts transplantation outcomes in pediatric patients. Blood 117(9):2728–2734. doi:10.1182/blood-2010-08-303263, blood-2010-08-303263 [pii]

    PubMed  CAS  Google Scholar 

  • Sobocinski KA, Thall PF, Bekele BN, Klein JP, Lennon S, Horowitz MM, Andersson B (2004) Matched pairs analysis of IV vs. PO busulfan as a conditioning agent prior to transplantation. ASH Annual Meeting Abstr 104(11):349

    Google Scholar 

  • Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, Storer B (2005) Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106(8):2912–2919. doi:10.1182/blood-2005-05-2004, 2005-05-2004 [pii]

    PubMed  CAS  Google Scholar 

  • Strahm B, Nollke P, Zecca M, Korthof ET, Bierings M, Furlan I, Sedlacek P, Chybicka A, Schmugge M, Bordon V, Peters C, O’Marcaigh A, de Heredia CD, Bergstraesser E, Moerloose BD, van den Heuvel-Eibrink MM, Stary J, Trebo M, Wojcik D, Niemeyer CM, Locatelli F (2011) Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome in children: results of the EWOG-MDS 98 study. Leukemia 25(3):455–462. doi:10.1038/leu.2010.297

    PubMed  CAS  Google Scholar 

  • Styczynski J, Tallamy B, Waxman I, van de Ven C, Milone MC, Shaw LM, Harrison L, Morris E, Satwani P, Bhatia M, George D, Bradley MB, Garvin JH, Schwartz J, Baxter-Lowe LA, Cairo MS (2011) A pilot study of reduced toxicity conditioning with BU, fludarabine and alemtuzumab before the allogeneic hematopoietic SCT in children and adolescents. Bone Marrow Transplant 46(6):790–799. doi:10.1038/bmt.2010.209

    PubMed  CAS  Google Scholar 

  • Suttorp M, Yaniv I, Schultz KR (2011) Controversies in the treatment of CML in children and adolescents: TKIs versus BMT? Biol Blood Marrow Transplant 17(1 Suppl):S115–S122. doi:10.1016/j.bbmt.2010.09.003, S1083-8791(10)00383-6 [pii]

    PubMed  Google Scholar 

  • Teshima T, Matsuo K, Matsue K, Kawano F, Taniguchi S, Hara M, Hatanaka K, Tanimoto M, Harada M, Nakao S, Abe Y, Wake A, Eto T, Takemoto Y, Imamura M, Takahashi S, Ishida Y, Kanda Y, Kasai M, Takaue Y (2005) Impact of human leucocyte antigen mismatch on graft-versus-host disease and graft failure after reduced intensity conditioning allogeneic haematopoietic stem cell transplantation from related donors. Br J Haematol 130(4):575–587

    PubMed  Google Scholar 

  • Thall PF, Champlin RE, Andersson BS (2004) Comparison of 100-day mortality rates associated with i.v. busulfan and cyclophosphamide vs other preparative regimens in allogeneic bone marrow transplantation for chronic myelogenous leukemia: Bayesian sensitivity analyses of confounded treatment and center effects. Bone Marrow Transplant 33(12):1191–1199. doi:10.1038/sj.bmt.1704461

    PubMed  CAS  Google Scholar 

  • Thomas ED, Buckner CD, Banaji M, Clift RA, Fefer A, Flournoy N, Goodell BW, Hickman RO, Lerner KG, Neiman PE, Sale GE, Sanders JE, Singer J, Stevens M, Storb R, Weiden PL (1977) One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood 49(4):511–533

    PubMed  CAS  Google Scholar 

  • Thornley I, Perentesis JP, Davies SM, Smith FO, Champagne M, Lipton JM (2003) Treating children with chronic myeloid leukemia in the imatinib era: a therapeutic dilemma? Med Pediatr Oncol 41(2):115–117. doi:10.1002/mpo.10306

    PubMed  Google Scholar 

  • Tiedemann K, Waters KD, Tauro GP, Tucker D, Ekert H (1993) Results of intensive therapy in childhood acute myeloid leukemia, incorporating high-dose melphalan and autologous bone marrow transplantation in first complete remission. Blood 82(12):3730–3738

    PubMed  CAS  Google Scholar 

  • Tse WT, Duerst R, Schneiderman J, Chaudhury S, Jacobsohn D, Kletzel M (2009) Age-dependent pharmacokinetic profile of single daily dose i.v. busulfan in children undergoing reduced-intensity conditioning stem cell transplant. Bone Marrow Transplant 44(3):145–156. doi:10.1038/bmt.2008.437

    PubMed  CAS  Google Scholar 

  • Tutschka PJ, Copelan EA, Klein JP (1987) Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 70:1382–1388

    PubMed  CAS  Google Scholar 

  • Uberti JP, Agovi MA, Tarima S, Haagenson M, Gandham S, Anasetti C, Baker KS, Bolwell BJ, Bornhauser M, Chan KW, Copelan E, Davies SM, Finke J, Hale GA, Kollman C, McCarthy PL, Ratanatharathorn V, Ringden O, Weisdorf DJ, Rizzo JD (2011) Comparative analysis of BU and CY versus CY and TBI in full intensity unrelated marrow donor transplantation for AML, CML and myelodysplasia. Bone Marrow Transplant 46(1):34–43. doi:10.1038/bmt.2010.81, bmt201081 [pii]

    PubMed  CAS  Google Scholar 

  • Vassal G, Deroussent A, Challine D, Hartmann O, Koscielny S, Valteau-Couanet D, Lemerle J, Gouyette A (1992) Is 600 mg/m2 the appropriate dosage of busulfan in children undergoing bone marrow transplantation? Blood 79(9):2475–2479

    PubMed  CAS  Google Scholar 

  • Veys P (2011) Reduced intensity transplantation for primary immunodeficiency disorders. Pediatr Rep 3(Suppl 2):e11. doi:10.4081/pr.2011.s2.e11, pr.2011.s2.e11 [pii]

    PubMed  Google Scholar 

  • Veys P, Wynn RF, Ahn KW, Samarasinghe S, He W, Bonney D, Craddock J, Cornish J, Davies SM, Dvorak CC, Duerst RE, Gross TG, Kapoor N, Kitko C, Krance RA, Leung W, Lewis VA, Steward C, Wagner JE, Carpenter PA, Eapen M (2012) Impact of immune modulation with in vivo T-cell depletion and myleoablative total body irradiation conditioning on outcomes after unrelated donor transplantation for childhood acute lymphoblastic leukemia. Blood 119(25):6155–6161. doi:10.1182/blood-2012-01-405795, blood-2012-01-405795 [pii]

    PubMed  CAS  Google Scholar 

  • Wachowiak J, Sykora KW, Cornish J, Chybicka A, Kowalczyk JR, Gorczynska E, Choma M, Grund G, Peters C (2011) Treosulfan-based preparative regimens for allo-HSCT in childhood hematological malignancies: a retrospective study on behalf of the EBMT pediatric diseases working party. Bone Marrow Transplant. doi:10.1038/bmt.2010.343

    PubMed  Google Scholar 

  • Wagner JE, Eapen M, MacMillan ML, Harris RE, Pasquini R, Boulad F, Zhang MJ, Auerbach AD (2007) Unrelated donor bone marrow transplantation for the treatment of Fanconi anemia. Blood 109(5):2256–2262. doi:10.1182/blood-2006-07-036657, blood-2006-07-036657 [pii]

    PubMed  CAS  Google Scholar 

  • Wall DA, Carter SL, Kernan NA, Kapoor N, Kamani NR, Brochstein JA, Frangoul H, Goyal RK, Horan JT, Pietryga D, Wagner JE, Kurtzberg J (2005) Busulfan/melphalan/antithymocyte globulin followed by unrelated donor cord blood transplantation for treatment of infant leukemia and leukemia in young children: the Cord Blood Transplantation study (COBLT) experience. Biol Blood Marrow Transplant 11(8):637–646. doi:10.1016/j.bbmt.2005.05.003, S1083879105002892 [pii]

    PubMed  CAS  Google Scholar 

  • Weisdorf DJ, Woods WG, Nesbit ME Jr, Uckun F, Dusenbery K, Kim T, Haake R, Thomas W, Kersey JH, Ramsay NK (1994) Allogeneic bone marrow transplantation for acute lymphoblastic leukaemia: risk factors and clinical outcome. Br J Haematol 86(1):62–69

    PubMed  CAS  Google Scholar 

  • Weisdorf DJ, Anasetti C, Antin JH, Kernan NA, Kollman C, Snyder D, Petersdorf E, Nelson G, McGlave P (2002) Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation. Blood 99(6):1971–1977

    PubMed  CAS  Google Scholar 

  • Yabe M, Sako M, Yabe H, Osugi Y, Kurosawa H, Nara T, Tokuyama M, Adachi S, Kobayashi C, Yanagimachi M, Ohtsuka Y, Nakazawa Y, Ogawa C, Manabe A, Kojima S, Nakahata T (2008) A conditioning regimen of busulfan, fludarabine, and melphalan for allogeneic stem cell transplantation in children with juvenile myelomonocytic leukemia. Pediatr Transplant 12(8):862–867. doi:10.1111/j.1399-3046.2008.00931.x

    PubMed  CAS  Google Scholar 

  • Yeager AM, Wagner JE Jr, Graham ML, Jones RJ, Santos GW, Grochow LB (1992) Optimization of busulfan dosage in children undergoing bone marrow transplantation: a pharmacokinetic study of dose escalation. Blood 80(9):2425–2428

    PubMed  CAS  Google Scholar 

  • Zwaveling J, Bredius RG, Cremers SC, Ball LM, Lankester AC, Teepe-Twiss IM, Egeler RM, den Hartigh J, Vossen JM (2005) Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity. Bone Marrow Transplant 35(1):17–23

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pediatric BMT Program, University of Michigan, Ann Arbor, Michigan

    John E. Levine MD, MS

  2. Children’s Hospital at Westmead, Sydney, Australia

    Peter J. Shaw MD

  3. Division of Hematology/Oncology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA

    Franklin O. Smith MD

Authors
  1. John E. Levine MD, MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter J. Shaw MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Franklin O. Smith MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John E. Levine MD, MS .

Editor information

Editors and Affiliations

  1. University of Cincinnati, Cincinnati, Ohio, USA

    Franklin O. Smith

  2. George Washington University, Washington, Washington, USA

    Gregory H. Reaman

  3. Division of Hematology/Oncology, Dept. of Internal Medicine, University of Cincinnati College of Medicine, Madeira, Ohio, USA

    Judy M. Racadio

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Levine, J.E., Shaw, P.J., Smith, F.O. (2014). Preparative Regimens. In: Smith, F., Reaman, G., Racadio, J. (eds) Hematopoietic Cell Transplantation in Children with Cancer. Pediatric Oncology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-39920-6_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-39920-6_3

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-39919-0

  • Online ISBN: 978-3-642-39920-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation